Escaline
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Escaline (3,5-dimethoxy-4-ethoxyphenethylamine) is a synthetic psychedelic of the phenethylamine class. It is the closest chemical relative of mescaline, distinguished by a single molecular change that makes it substantially more potent. It activates serotonin receptors in the brain, producing the visual distortions and emotional shifts characteristic of the mescaline family.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
lsd, psilocybin, mescaline +2 morelsd, psilocybin, mescaline, dmt, 2c-b show less
Escaline was first synthesized in 1954 by Benington, Morin, and Clark while studying mescaline analogs.[3] Alexander Shulgin published the first detailed human records in PiHKAL in 1991.[4] It remains a niche compound — classified as Schedule I in the United States, with limited circulation primarily among research chemical enthusiasts.
Subjective effects include geometric visual patterns, color enhancement, emotional warmth, thought connectivity, and time alteration. The experience is broadly mescaline-like — a warm, body-centered psychedelia — but with faster onset and notably less nausea.[4] Motor incoordination, disrupted sleep, and day-after fatigue are characteristic unwanted effects.[4]
Escaline produces no physical dependence, and no lethal dose has been established in any species.safety citation needed The primary risks are psychological — panic, anxiety, and psychosis in predisposed individuals — alongside cardiovascular stimulation that poses danger for those with heart conditions.[5][4] No human clinical trials exist — all evidence comes from lab binding studies, animal tests, and Shulgin's personal records.
History[edit]
Discovery
Escaline was first synthesized in 1954 by Benington, Morin, and Clark during a systematic study of mescaline analogs.[3] In 1977, Nichols and Dyer showed that replacing mescaline's methoxy group at the 4-position with a larger ethoxy group substantially increased its potency at serotonin receptors.[6]
Human documentation
Alexander Shulgin independently prepared escaline and published the first detailed human records in PiHKAL: A Chemical Love Story (1991), listing it as compound #72.[4] He described it as qualitatively similar to mescaline but with faster onset and less nausea. His self-experiment records remain the only published human data on escaline's subjective effects.
Research chemical era and scheduling
Escaline appeared on the unregulated research chemical market in the 2000s,citation needed classified as Schedule I in the United States (DEA #7930) and banned in Sweden in 2016. The United Kingdom's Psychoactive Substances Act 2016 provides blanket coverage. A 2012 review by Trachsel used escaline as a reference compound in structure–activity research on the phenethylamine family.[7]
The name "escaline" derives from its position in the scaline series — a family of 3,5-dimethoxy-4-alkoxyphenethylamines named by extending the suffix from mescaline. The series includes Mescaline (methoxy), escaline (ethoxy), proscaline (propoxy), and higher homologues, each a single carbon extension at the 4-position. Escaline occupies a quiet corner of psychedelic culture: too obscure for widespread recognition, it circulates mainly among collectors of Shulgin's catalog and researchers exploring the mescaline family's structure–activity landscape.
Chemistry[edit]
Structural class
Escaline belongs to the scaline series — a family of mescaline analogs. It differs from mescaline by a single structural change: the methoxy group at the 4-position is replaced with an ethoxy group, one carbon longer. This change substantially increases its binding affinity at serotonin receptors.[6][8] Its molecular formula is C₁₂H₁₉NO₃.[2]
Molecular properties
| Molecular formula | C₁₂H₁₉NO₃ |
| Molecular weight | 225.28 g/mol |
Pharmacology[edit]
Mechanism of action
Escaline produces its psychedelic effects by activating serotonin receptors in the brain.[9][10] This is confirmed by class studies: drugs that block those serotonin receptors also block mescaline's psychedelic effects in human trials,[5] and escaline shares both the receptor target and the molecular scaffold.
It binds serotonin receptors with roughly 43 times greater affinity than mescaline,[1][2][8] translating to approximately 5–8× greater potency in practice.[7] It also activates a closely related serotonin receptor subtype[8][11] but has negligible activity at dopamine receptors.[8]
Pharmacokinetics
No human pharmacokinetic studies have been published — timing estimates are extrapolated from mescaline and from Shulgin's observations.[4] As a phenethylamine without the protective methyl group present in amphetamines, escaline is presumed to be metabolized by monoamine oxidase enzymes — the same primary pathway that processes mescaline.[12]
Neuroscience[edit]
Where it acts
No brain imaging or electrophysiology data exist for escaline specifically. Based on its behavioral activity,[13] it is expected to act on neurons in the prefrontal cortex[9] — the same circuits engaged by other serotonergic psychedelics. Controlled mescaline trials show alterations comparable to LSD and psilocybin on standardized measures,[14] suggesting escaline engages equivalent circuitry at proportionally lower doses.
Why it matters
One influential framework proposes that serotonin-activating psychedelics loosen the brain's top-down predictive filters — the mental shortcuts that ordinarily shape raw perception into a coherent world. When those filters relax, sensory data overrides expectation, producing the visual distortions and novel thought patterns characteristic of the mescaline class. Tolerance develops within 24 hours as serotonin receptors downregulate in response.[15]
- Does escaline's increased lipophilicity alter its distribution in the brain, receptor residence time, or time-to-peak effects compared to mescaline?
- What accounts for the non-linear translation between escaline's 43-fold increase in receptor affinity and its 5–8× increase in human potency?
- Does escaline show a different activation pattern at serotonin receptors compared to mescaline, potentially explaining its reduced nausea and increased motor impairment?
Subjective Effects[edit]
Escaline produces a warm, body-centered psychedelia in the mescaline tradition.[4] Colors intensify, surfaces shimmer, and geometry emerge and evolve. The emotional register is expansive and open — a connected warmth that runs through the experience from beginning to end.
Among better-known psychedelics, escaline sits closest to Mescaline in character, sharing its embodied warmth and prominent visual dimension. Compared to tryptamine psychedelics like psilocybin, the experience is more grounded in sensation and less introspective.[14] Motor coordination is more noticeably affected than with either compound.
Effect Grid
At common doses (40-60 mg oral), escaline produces its full psychedelic character as described in Shulgin's PiHKAL bioassays. Visual hallucinations become prominent — geometric patterns, color shifts, and surface drifting. Thought connectivity increases substantially, producing enhanced associative thinking and personal insight. Time distortion is noticeable. Emotional responses to stimuli intensify.
Physically, tachycardia, muscle tension, and dehydration are expected. Motor incoordination may emerge, particularly at the upper end of this range. Nausea is less pronounced than with mescaline but may still occur. Analgesia has been reported.
The full experience lasts 8-12 hours with a faster onset than mescaline (within the first hour). Sleep may be difficult for several hours after subjective effects resolve, and some subjects report nightmare-quality sleep and next-day tiredness.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual breathing · Touch enhancement · Tracers · Symmetrical texture repetition · Depth perception distortion · Environmental patterning · Light sensitivity · Music enhancement · Sound sensitivity · Visual morphing · Holotropic state · After-images · Auditory enhancement · Peripheral vision distortion · Perspective distortion · Synesthesia · Visual haze / noise · Visual melting · Visual acuity enhancement · Auditory distortion · Auditory misinterpretation · Proprioceptive distortion · Spatial disorientation · Visual diffraction · Peripheral misidentification · Vestibular distortion · Visual magnification · Taste enhancement · Visual processing acceleration · Visual acuity suppression · Flashbacks · Object transformations · External hallucinations · Internal hallucinations · Environmental orbism / cubism · Object activation · Visual recursion · Perspective hallucinations · Visual scenery slicing · Auditory hallucinations · Persisting hallucinations
Depth perception distortion · Environmental patterning · Light sensitivity · Music enhancement · Sound sensitivity · Visual morphing · Holotropic state · After-images · Auditory enhancement · Peripheral vision distortion · Perspective distortion · Synesthesia · Visual haze / noise · Visual melting · Visual acuity enhancement · Auditory distortion · Auditory misinterpretation · Proprioceptive distortion · Spatial disorientation · Visual diffraction · Peripheral misidentification · Vestibular distortion · Visual magnification · Taste enhancement · Visual processing acceleration · Visual acuity suppression · Flashbacks · Object transformations · External hallucinations · Internal hallucinations · Environmental orbism / cubism · Object activation · Visual recursion · Perspective hallucinations · Visual scenery slicing · Auditory hallucinations · Persisting hallucinations
Nausea · Body high · Spontaneous body sensations · Wakefulness · Muscle tension · Appetite suppression · Dizziness · Dry mouth · Heart rate perception changes · Insomnia · Restlessness · Tingling / electric sensations · Bodily lightness · Excessive sweating · Laughter fits · Physical fatigue · Tactile euphoria · Temperature dysregulation · Vibrations / buzzing · Vomiting · Bodily pressures · Body schema distortion · Breathing alteration · Headache · Kundalini-like energy · Sexual arousal enhancement · Trembling · Vasoconstriction · Diarrhea · Nystagmus (eye wobbles) · Salivation · Bodily dissociation
Wakefulness · Muscle tension · Appetite suppression · Dizziness · Dry mouth · Heart rate perception changes · Insomnia · Restlessness · Tingling / electric sensations · Bodily lightness · Excessive sweating · Laughter fits · Physical fatigue · Tactile euphoria · Vibrations / buzzing · Vomiting · Bodily pressures · Body schema distortion · Breathing alteration · Headache · Kundalini-like energy · Sexual arousal enhancement · Trembling · Vasoconstriction · Diarrhea · Nystagmus (eye wobbles) · Salivation · Bodily dissociation
Aesthetic enhancement · Introspection enhancement · Openness enhancement · Thought connectivity · Immersion enhancement · Cognitive flexibility · Thought acceleration · Cognitive euphoria · Increased nature relatedness · Multiple thought streams · Creativity enhancement · Memory suppression · Humor enhancement · Cognitive impairment · Focus suppression · Synchronicity · Thought loops · Analysis enhancement · Confusion · Memory fragmentation · Thought disorganization · Information processing enhancement · Language enhancement · Cognitive dysphoria · Delusions
Thought connectivity · Immersion enhancement · Cognitive flexibility · Thought acceleration · Cognitive euphoria · Increased nature relatedness · Multiple thought streams · Creativity enhancement · Memory suppression · Humor enhancement · Cognitive impairment · Focus suppression · Synchronicity · Thought loops · Analysis enhancement · Confusion · Memory fragmentation · Thought disorganization · Information processing enhancement · Language enhancement · Cognitive dysphoria
Simultaneous emotions · Anxiety · Catharsis · Anxiety suppression · Dysphoria · Irritability
Dysphoria · Irritability
Trust enhancement · Communication enhancement · Flow state · Depersonalization · Disinhibition · Boundary dissolution · Ego dissolution · Identity alteration · Telepathic feelings
Disinhibition · Boundary dissolution · Ego dissolution · Identity alteration · Telepathic feelings
Transpersonal visions · Death-rebirth sequence · Entity contact
Timeline
First alerts emerge within 20-45 minutes — subtle mood shift, mild visual brightening, and a sense that something has changed. Faster than mescaline's typical onset.
Effects build steadily over 30-60 minutes. Visual field begins to shimmer, colors intensify, and body awareness increases. Mild nausea or stomach discomfort may occur but is typically less pronounced than with mescaline.
Full psychedelic intensity sustained for 2-4 hours. Visual hallucinations, thought connectivity, personal insight, and time distortion reach maximum. Motor incoordination and tachycardia are most pronounced during this phase.
Intensity gradually diminishes over 2-3 hours while retaining psychedelic character. Visual effects soften, cognitive clarity begins to return. Emotional processing and reflective thinking often prominent.
Gradual return toward baseline over 1. 5-3 hours. Residual visual enhancement and mild thought alteration persist.
Residual effects persist for 6-24 hours post-resolution. Shulgin noted next-day tiredness and low energy in some subjects. Sleep quality may be impaired, with nightmare-quality sleep reported.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- lsd · psilo · mesc
The safety profile of escaline is uncharacterized by controlled study. No lethal dose, overdose cases, or systematic adverse event data exist. All assessments below are drawn from Shulgin's observations, structural analogy to mescaline, and class-level data on serotonergic psychedelics.
Toxicity
No lethal dose has been established for escaline in any species,safety citation needed and no human fatalities have been reported in the published literature.
Heart and circulation
Escaline is expected to raise blood pressure and heart rate, consistent with mescaline's cardiovascular profile in controlled trials.[5] Rapid heartbeat was explicitly documented in Shulgin's records.[4]
Gastrointestinal effects
Escaline produces less nausea than mescaline.[4] The reason for this reduced emetic profile is unknown.
Other physical effects
Muscle tension, dehydration, and motor incoordination were documented in Shulgin's records, with motor impairment worsening at higher doses.[4] No organ-specific toxicity has been reported.
Psychological risks
Acute anxiety and panic reactions are the most common adverse outcome, more likely at higher doses or in uncontrolled settings. Psychosis precipitation poses elevated risk for anyone with a personal or family history of psychotic disorders — serotonin receptor activation can trigger acute psychotic episodes. Persistent visual disturbances after the experience ends (a condition called HPPD) have been documented for phenethylamine psychedelics; no escaline-specific cases exist.
Shulgin reported disrupted sleep with nightmare-quality dreams and residual fatigue the following day in some subjects.[4]
Tolerance and dependence
Tolerance develops within 24 hours of a single dose — serotonin receptors in the frontal cortex downregulate, reducing the compound's effects.[15] This makes compulsive redosing self-limiting. Recent use of LSD, psilocybin, or mescaline will diminish escaline's effects through cross-tolerance.[10][15]
serotonin 2A receptor agonists as a class do not produce physical dependence or compulsive drug-seeking behavior.citation needed
Drug interactions
Tramadol — tramadol slows serotonin clearance and has mild serotonin-activating properties.[16] Combined with escaline's direct serotonin receptor activation, this creates conditions for dangerous overheating, seizure-like muscle jerking, and agitation — a potentially fatal reaction.
MAOIs — monoamine oxidase inhibitors slow escaline's metabolic clearance while simultaneously raising serotonin levels.safety citation needed The result is both higher drug exposure and additive serotonin syndrome. This combination is potentially fatal.
SSRIs and SNRIs — These medications may blunt escaline's effects through receptor adaptation, or conversely increase the risk of serotonin toxicity.safety citation needed
Lithium — Combined with classic psychedelics, lithium has been associated with seizure risk.safety citation needed
Other 5-HT₂A agonists — Including other psychedelics — produce additive effects and should not be combined.
Cannabis — No interaction data exist. The combination is unstudied.
Contraindications
- Severe heart conditions — Escaline's expected blood pressure and heart rate elevation[5] creates risk of serious cardiovascular events.
- Personal or family history of psychotic disorders — Serotonin receptor activation can trigger acute psychotic episodes.
- Concurrent serotonergic medication — MAOIs, SSRIs, SNRIs, and tramadol are contraindicated due to serotonin syndrome risk.[16]
- Pregnancy and breastfeeding — No reproductive or developmental safety data exist.
No escaline-specific contraindication data have been published — all entries above are inferred from class-level evidence and analogy to mescaline.
Harm Reduction[edit]
Forms & Identification
Escaline circulates almost exclusively as a powder or crystalline solid, typically as the hydrochloride salt. Its obscurity creates real mislabeling risk — vendors may confuse it with other scaline-series compounds (proscaline, isoproscaline) or unrelated phenethylamines. Reagent testing can confirm the presence of a phenethylamine but cannot distinguish between members of the scaline family. A drug checking service is the only reliable way to confirm identity and purity.
Guidelines
- Test all material with a reagent kit before use; use a drug checking service if available to confirm identity
- Weigh doses with a milligram-precision scale — volumetric dosing is unreliable for powders at this potency range
- Start at the low end of the active range and wait at least two hours before considering any supplemental dose
- Eat a light meal 2–3 hours before to reduce nausea risk without a full stomach
- Stay hydrated throughout — dehydration was noted in early records
- Plan for the full duration: 8–12 hours of primary effects plus sleep disruption afterward
- Have a sober, trusted sitter present, especially for unfamiliar doses
Set & Setting
Escaline's long duration demands careful planning. Choose a physically safe, comfortable environment with access to water, food, and a place to rest. A sober sitter familiar with psychedelic experiences is strongly recommended, especially for first experiences or higher doses.
Set aside the full day plus the following morning — residual fatigue and disrupted sleep are common. Avoid situations requiring coordination or quick judgment, as motor impairment increases at higher doses.
Aftercare & integration. The day after an escaline experience often brings fatigue and low energy — plan for rest and avoid demanding obligations. Disrupted sleep with vivid or unsettling dreams is common and typically resolves within one to two nights.
Journaling within 24–48 hours helps capture insights before they fade. If the experience was emotionally intense or raised difficult material, talking with a trusted friend or a therapist experienced with psychedelic integration can help process it. Persistent anxiety, mood disturbance, or visual changes lasting more than a week warrant professional consultation.
Recovery & Support
Escaline does not produce physical dependence, and compulsive use patterns are rare among serotonin-activating psychedelics. If psychedelic use is becoming a pattern of avoidance or is interfering with daily functioning, support resources include psychedelic integration therapists, peer support organizations such as the Fireside Project (62-FIRESIDE), and broader mental health services. The issue is rarely the substance itself — it is usually what the substance is being used to manage.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Most difficult escaline experiences involve intense anxiety or panic rather than medical emergencies. Recognizing the difference matters.
Uncomfortable but manageable: anxiety, nausea, confusion, visual intensity, thought loops, muscle tension. Distressing but not dangerous — calm reassurance and a quiet environment usually help.
Needs immediate help: chest pain, sustained rapid heartbeat with dizziness, loss of consciousness, self-harm behavior, complete disconnection from reality with inability to respond to verbal contact, dangerous overheating.
- 1. Call emergency services if any red flags above appear
- 2. Move the person to a quiet, safe space and reduce sensory stimulation
- 3. Do not restrain them unless there is immediate danger of self-harm
- 4. If unconscious, place in the recovery position
- 5. Stay with them until help arrives
What to tell the dispatcher: the substance name (escaline, a psychedelic phenethylamine), the approximate amount taken, when it was taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Escaline is specifically scheduled in the United States and Sweden, covered by blanket psychoactive substance laws in the United Kingdom and reportedly Germany, and uncontrolled in several other jurisdictions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (DEA #7930) | Specifically scheduled; also covered by Federal Analogue Act (21 U.S.C. § 813) as substantially similar to mescalinecitation needed |
| Sweden | Illegal | Classified since January 26, 2016citation needed |
| United Kingdom | Psychoactive Substances Act 2016 | Blanket prohibition effective May 26, 2016; not specifically listed under Misuse of Drugs Act 1971 |
| Germany | Reportedly NpSG-covered | Neue-psychoaktive-Stoffe-Gesetz effective November 2016; specific listing not directly verifiedcitation needed |
| Canada | Not controlled | Not listed as a controlled substance as of 2025 |
| Australia | Not specifically scheduled | May be covered by state-level analog provisions; status unverified |
Analog and classification considerations
The DEA Schedule I classification under number 7930 has been attributed in some secondary sources to positional isomer classification relative to 3,4,5-trimethoxyamphetamine (TMA). This is chemically questionable — escaline is a phenethylamine, not an amphetamine — and the scheduling rationale should be verified against the current DEA Orange Book.citation needed
In jurisdictions without specific scheduling, escaline's structural similarity to mescaline makes it vulnerable to prosecution under structural analog or "substantially similar" provisions.
Legal status changes frequently and varies by jurisdiction. This information reflects available sources as of 2025 and is not legal advice. Verify current status before making decisions based on it.
references
- [1] ^abBlaazer AR, Smid P, Kruse CG (2008) Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors — ChemMedChem doi:10.1002/cmdc.200800133
- [2]
- [3]
- [4]
- [5] ^abcdKlaiber A, Schmid Y, Becker AM, Straumann I, Erne L, Jelusic A, Thomann J, Luethi D, Liechti ME (2024) Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects — Translational Psychiatry doi:10.1038/s41398-024-03116-2
- [6] ^abNichols DE, Dyer DC (1977) Lipophilicity and serotonin agonist activity in a series of 4-substituted mescaline analogues — Journal of Medicinal Chemistry PMID:836502